LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Home・Akciju saraksts・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Slēgts

2.6 -0.38

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.59

Max

2.61

Galvenie mērījumi
By Trading Economics
Ienākumi	-6.4M -53M
Pārdošana	-9.6M 47M
Peļņas marža	-112.813
Darbinieki	580
EBITDA	-28M -49M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+64.75% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2025. g. 6. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-22M 753M
Iepriekšējā atvēršanas cena	2.98
Iepriekšējā slēgšanas cena	2.6

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

2.02 / 2.115 Atbalsts un pretestība

Maravai LifeSciences Holdings Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. aug. 16:11 UTC

Galvenie tirgus virzītāji

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

2025. g. 15. aug. 22:22 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 15. aug. 22:22 UTC

Tirgus saruna

Target Is Falling Behind Its Peers -- Market Talk

2025. g. 15. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. aug. 20:33 UTC

Tirgus saruna

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

2025. g. 15. aug. 20:25 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

2025. g. 15. aug. 20:24 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025. g. 15. aug. 20:18 UTC

Peļņas

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025. g. 15. aug. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

2025. g. 15. aug. 19:12 UTC

Tirgus saruna

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

2025. g. 15. aug. 18:32 UTC

Tirgus saruna

Coffee Futures Surge on New Brazilian Frost -- Market Talk

2025. g. 15. aug. 17:33 UTC

Tirgus saruna

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

2025. g. 15. aug. 17:23 UTC

Tirgus saruna

Peļņas

Deere's Earnings Appear to Be Troughing -- Market Talk

2025. g. 15. aug. 16:27 UTC

Peļņas

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

2025. g. 15. aug. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. aug. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. aug. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 15. aug. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

2025. g. 15. aug. 15:52 UTC

Iegādes, apvienošanās, pārņemšana

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

2025. g. 15. aug. 15:36 UTC

Tirgus saruna

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

2025. g. 15. aug. 15:29 UTC

Peļņas

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

2025. g. 15. aug. 15:29 UTC

Iegādes, apvienošanās, pārņemšana

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

2025. g. 15. aug. 15:28 UTC

Peļņas

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

2025. g. 15. aug. 15:24 UTC

Tirgus saruna

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

2025. g. 15. aug. 15:08 UTC

Tirgus saruna

Applied Materials Is Losing Share in Chips Business -- Market Talk

2025. g. 15. aug. 14:38 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

2025. g. 15. aug. 14:37 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

2025. g. 15. aug. 14:37 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

2025. g. 15. aug. 14:36 UTC

Iegādes, apvienošanās, pārņemšana

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

2025. g. 15. aug. 14:33 UTC

Iegādes, apvienošanās, pārņemšana

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Maravai LifeSciences Holdings Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

64.75% augšup

Prognoze 12 mēnešiem

Vidējais 4.3 USD 64.75%

Augstākais 5 USD

Zemākais 2.5 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.02 / 2.115Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.